Clinical Research Directory
Browse clinical research sites, groups, and studies.
Radiotherapy vs Neck Dissection for Clinical T1/2N0 Supraglottic Cancer
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Summary
Supraglottic cancer is a main type of laryngeal carcinoma, which is one of the most common head and neck tumors. Cervical nodal metastasis is an important prognostic factor in supraglottic cancer. Current management, following the US National Comprehensive Cancer Network guidelines for T1-2, N0 supraglottic cancer (NCCN 2017), is either definitive radiotherapy or primary surgery with or without neck dissection. The optimal neck treatments strategy remains unclear in clinical settings owing to the limitation of a small number of retrospective studies and a lack of prospective trials. The investigators conducted a prospective, randomised trial to compare radiotherapy with neck dissection.
Official title: Radiotherapy Versus Elective Neck Dissection for Management of Cervical Nodes in Clinical T1/2N0 Supraglottic Squamous Cell Carcinoma
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
158
Start Date
2017-12-20
Completion Date
2027-11-01
Last Updated
2017-12-12
Healthy Volunteers
No
Conditions
Interventions
Radiotherapy
Radiotherapy with a dose of 66-70 Gy is used to manage the cervical lymph nodes
Selective neck dissection
Selective neck dissection, defined as surgical clearance of the upper jugular (leveI II), midjugular (level III) and sometimes submandibular (level I) nodes, is used to manage the cervical lymph nodes
Locations (1)
Tianjin Medical University Cancer Institute and Hopital
Tianjin, Tianjin Municipality, China